Cargando…

Therapeutic responses to chemotherapy or immunotherapy by molecular subtype in bladder cancer patients: A meta-analysis and systematic review

To systematically evaluate the differences in therapeutic response to chemotherapy or immunotherapy between different molecular subtypes of bladder cancer (BC). A comprehensive literature search was performed up to December 2021. Consensus clusters 1 (CC1), CC2 and CC3 molecular subtypes were used t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Shunde, Yuan, Xiaoyu, Shen, Zhongjie, Zhao, Jiaming, Zheng, Baishu, Zhang, Junyong, Ge, Chengguo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Urological Association 2023
Materias:	Special Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172042/ https://www.ncbi.nlm.nih.gov/pubmed/37341003 http://dx.doi.org/10.4111/icu.20230015

Ejemplares similares

NUF2 is correlated with a poor prognosis and immune infiltration in clear cell renal cell carcinoma
por: Zheng, Baishu, et al.
Publicado: (2023)

Cardiovascular Mortality Risk in Patients with Bladder Cancer: A Population-Based Study
por: Wang, Shunde, et al.
Publicado: (2022)

High risk of non-cancer mortality in bladder cancer patients: evidence from SEER-Medicaid
por: Wang, Shunde, et al.
Publicado: (2023)

Identification of an immunotherapy-responsive molecular subtype of bladder cancer
por: Song, Bic-Na, et al.
Publicado: (2019)

M7G-related molecular subtypes can predict the prognosis and correlate with immunotherapy and chemotherapy responses in bladder cancer patients
por: Li, Deng-xiong, et al.
Publicado: (2023)

Multiomics analysis of ferroptosis-related molecular subtypes in muscle-invasive bladder cancer immunotherapy
por: Wang, Haojie, et al.
Publicado: (2022)

DNA Methylation Modification Map to Predict Tumor Molecular Subtypes and Efficacy of Immunotherapy in Bladder Cancer
por: Ye, Fangdie, et al.
Publicado: (2021)

A risk model based on pyroptosis subtypes predicts tumor immune microenvironment and guides chemotherapy and immunotherapy in bladder cancer
por: Wu, Tielin, et al.
Publicado: (2022)

Update on bladder cancer molecular subtypes
por: Fong, Megan Hoi Yan, et al.
Publicado: (2020)

Predictive value of molecular subtypes and APOBEC3G for adjuvant chemotherapy in urothelial bladder cancer
por: Olah, Csilla, et al.
Publicado: (2022)

Role of adjuvant cisplatin-based chemotherapy following radical cystectomy in locally advanced muscle-invasive bladder cancer: Systematic review and meta-analysis of randomized trials
por: Kim, Do Kyung, et al.
Publicado: (2019)

Identification of immunotherapy and chemotherapy-related molecular subtypes in colon cancer by integrated multi-omics data analysis
por: Zhu, Jie, et al.
Publicado: (2023)

Apoptosis related genes mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide immunotherapy in bladder cancer
por: Zhou, Liquan, et al.
Publicado: (2023)

Evaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer
por: Wucherpfennig, Sophie, et al.
Publicado: (2021)

Global Development of Anticancer Therapies for Rare Cancers, Pediatric Cancers, and Molecular Subtypes of Common Cancers
por: Lyerly, H. Kim, et al.
Publicado: (2018)

Neoadjuvant cisplatin-based chemotherapy in “primary” and “secondary” muscle-invasive bladder cancer—is it a surrogate for molecular subtypes?
por: Szarvas, Tibor, et al.
Publicado: (2019)

Molecular subtyping bladder cancer: Is it ready for clinical practice?
por: VAKAR LOPEZ, Funda
Publicado: (2020)

Integrated molecular analyses of an interferon-γ based subtype with regard to outcome, immune characteristics, and immunotherapy in bladder cancer and experimental verification
por: Wang, Jirong, et al.
Publicado: (2022)

A cancer-associated fibroblast subtypes-based signature enables the evaluation of immunotherapy response and prognosis in bladder cancer
por: Qin, Yiming, et al.
Publicado: (2023)

Molecular Subtypes as a Basis for Stratified Use of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer—A Narrative Review
por: Sjödahl, Gottfrid, et al.
Publicado: (2022)

Squamous cell carcinoma of the renal parenchyma presenting as hydronephrosis: a case report and review of the recent literature
por: Zhang, Xirong, et al.
Publicado: (2020)

Causal effects of inflammatory bowel diseases on the risk of kidney stone disease: a two-sample bidirectional mendelian randomization
por: Zhang, Huayang, et al.
Publicado: (2023)

Tumor Microenvironment Analysis Identified Subtypes Associated With the Prognosis and the Tumor Response to Immunotherapy in Bladder Cancer
por: Zhang, Hongxian, et al.
Publicado: (2021)

Risk Classification of Bladder Cancer by Gene Expression and Molecular Subtype
por: Blanca, Ana, et al.
Publicado: (2023)

Identification of endothelial-related molecular subtypes for bladder cancer patients
por: Li, Deng-xiong, et al.
Publicado: (2023)

The era of personalized treatments: Updates on immunotherapy within urothelial of bladder cancer
por: Wu, Zhang-Song, et al.
Publicado: (2022)

SULT1A1 Arg213His Polymorphism is Associated with Bladder Cancer Risk: A Meta-Analysis
por: Li, Wencheng, et al.
Publicado: (2014)

Multi-Omics Characterization of Tumor Microenvironment Heterogeneity and Immunotherapy Resistance Through Cell States–Based Subtyping in Bladder Cancer
por: Hu, Rixin, et al.
Publicado: (2022)

Damage-associated molecular patterns and sensing receptors based molecular subtypes in malignant pleural mesothelioma and implications for immunotherapy
por: Liu, Zheng, et al.
Publicado: (2023)

Immunohistochemical based molecular subtypes of muscle-invasive bladder cancer: association with HER2 and EGFR alterations, neoadjuvant chemotherapy response and survival
por: Helal, Duaa S., et al.
Publicado: (2023)

Targeted Therapy, Chemotherapy, Immunotherapy and Novel Treatment Options for Different Subtypes of Salivary Gland Cancer
por: Mueller, Sarina K., et al.
Publicado: (2022)

Crosstalk of four kinds of cell deaths defines subtypes of cutaneous melanoma for precise immunotherapy and chemotherapy
por: Wan, Qi, et al.
Publicado: (2022)

Recombinant allergens for immunotherapy: state of the art
por: Zhernov, Yury, et al.
Publicado: (2019)

Novel vaccines for allergen-specific immunotherapy
por: Akinfenwa, Oluwatoyin, et al.
Publicado: (2021)

Molecular subtyping of bladder cancer using Kohonen self-organizing maps
por: Borkowska, Edyta M, et al.
Publicado: (2014)

Epigenetic profiling demarcates molecular subtypes of muscle-invasive bladder cancer
por: van der Vos, K. E., et al.
Publicado: (2020)

Integrative analysis of immune molecular subtypes and microenvironment characteristics of bladder cancer
por: Cao, Jinlong, et al.
Publicado: (2021)

High-Content Drug Discovery Targeting Molecular Bladder Cancer Subtypes
por: Rinaldetti, Sébastien, et al.
Publicado: (2022)

Molecular subtypes, tumor microenvironment infiltration characterization and prognosis model based on cuproptosis in bladder cancer
por: Zhang, Heping, et al.
Publicado: (2023)

Identification of molecular subtypes based on liquid–liquid phase separation and cross-talk with immunological phenotype in bladder cancer
por: Sun, Le, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vkh0k00v80nb8oeshjtsutee5o